Curis (CRIS) Cash from Investing Activities (2010 - 2025)
Curis (CRIS) reported Cash from Investing Activities of $2.5 million for Q4 2025, up 684.11% on a YoY basis from $318831.9 in Q4 2024, and up 684.11% quarter-over-quarter from -$428000.0 in Q4 2024.
Curis (CRIS) Cash from Investing Activities (2010 - 2025) Analysis & Trends
Curis has reported Cash from Investing Activities for 16 years, with the latest figure at $2.5 million in Q4 2025.
- For the quarter ending Q4 2025, Cash from Investing Activities rose 684.11% year-over-year to $2.5 million; the trailing twelve-month figure through Mar 2026 stood at $2.5 million (down 76.26% YoY), and the FY2025 full-year result was $2.5 million, down 91.51% from the prior year.
- Cash from Investing Activities for Q4 2025 stood at $2.5 million, up from -$428000.0 in the prior quarter.
- The five-year high for Cash from Investing Activities was $28.3 million in Q2 2022, with the low at -$28.8 million in Q2 2021.
- Historically, Cash from Investing Activities has averaged $3.2 million across 5 years, with a median of $180000.0 in 2023.
- Annual changes were most pronounced in 2021 — Cash from Investing Activities plunged 11051.55% — and 2024, when it jumped 10076.67%.
- Curis' Cash from Investing Activities stood at -$3.5 million in 2021, then jumped by 198.3% to $3.5 million in 2022, then jumped by 319.2% to $14.5 million in 2023, then slumped by 102.95% to -$428000.0 in 2024, then surged by 684.11% to $2.5 million in 2025.
- The last three Cash from Investing Activities figures came in at $2.5 million (Q4 2025), -$428000.0 (Q4 2024), and $18.3 million (Q3 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | -2.89 Mn |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | 638.50 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | - |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | -431.90 Mn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | 579,519.10 |
| 10 | Curis | 8.58 Mn | -6.42 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.50 Mn |
| Dec 31, 2025 | 2.50 Mn |
| Dec 31, 2024 | -428,000.00 |
| Dec 31, 2024 | -428,000.00 |
| Sep 30, 2024 | 18.32 Mn |
| Sep 30, 2024 | 18.32 Mn |
| Jun 30, 2024 | -7.36 Mn |
| Jun 30, 2024 | -7.36 Mn |
| Mar 31, 2024 | 18.91 Mn |
| Mar 31, 2024 | 18.91 Mn |
| Dec 31, 2023 | 14.52 Mn |
| Dec 31, 2023 | 14.52 Mn |
| Sep 30, 2023 | 180,000.00 |
| Sep 30, 2023 | 180,000.00 |
| Jun 30, 2023 | -3.15 Mn |
| Jun 30, 2023 | -3.15 Mn |
| Mar 31, 2023 | 26.24 Mn |
| Mar 31, 2023 | 26.24 Mn |
| Dec 31, 2022 | 3.46 Mn |
| Dec 31, 2022 | 3.46 Mn |